Listen on the go
CORRECT!
Next question
touchHAEMATOLOGY touchHAEMATOLOGY

Start Learning

Touch Loading image
JOURNALS
Start Learning
#EHA2025: Lower-intensity AML therapies show high response rates in early trials
JOURNALS
Start Learning
‘BEST OF ASH24’: Perspectives from the Scientific Program Co-Chairs
CONFERENCE HUB
Start Learning
DREPAGREFFE: Comparing stem cell transplantation and standard-of-care in paediatric sickle cell anaemia
touchCONGRESS
Start Learning
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
CE/CME ACCREDITED
JOURNALS
Start Learning
Dr Esra Gülderen on learning, leadership and lifelong growth: touchHAEMATOLOGY Future Leader 2025
JOURNALS
Start Learning
Front-line ibrutinib-rituximab improves survival in mantle cell lymphoma
CONFERENCE HUB
Start Learning
Should we intensify chemotherapy in the treatment of acute myeloid leukemia? Insights from ASH 2024
JOURNALS
Start Learning
Q&A with Dr Marlies Vanden Bempt: touchHAEMATOLOGY Future Leader 2025
CONFERENCE HUB
Start Learning
Key highlights from ASH 2024: Promising new therapies for relapsed/refractory acute myeloid leukaemia
Madrid
JOURNALS
Start Learning
EHA 2024: Highlights of the late-breaking abstracts

to view Favourites, Keep Notes and Track CME Credits

Favourites
BVd compared to DVd in RRMM: The DREAMM-7 trial
View
#ASCO25: Dr Miguel-Angel Perales unveils the CAR T Vision Coalition
View
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
View
Bridging the gap in paediatric sickle cell care: Expanding transplant access globally
View
Very early FDG-PET/CT response-adapted therapy for advanced Hodgkin lymphoma
View
#EHA2025: Lower-intensity AML therapies show high response rates in early trials
View
#EHA2025 late-breaker: REDIRECTT-1: teclistamab + talquetamab show durable responses in EMD in multiple myeloma
View
#ASH24: Discover the 2024 late-breaking abstracts
View
Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma: From optimal sequencing to shared decision-making
View
Front-line ibrutinib-rituximab improves survival in mantle cell lymphoma
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup